CTLA4 and renal cell carcinoma: At the same time, it is important to note that the absence of a complete antitumor response in the RCC (Renca) model points out that further improvements of the antitumor immunity may require combinations with other PD-1 or CTLA4 immune checkpoint inhibitors, for example, TIM-3 or LAG3, which are commonly expressed in human RCC (38, 39).